Neuroendocrine tumors future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Neuroendocrine tumors}} {{CMG}} == Overview == ==Future or Investigational Therapies== Therapies based on growth factor inhibitors are in the experimental stage....") |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Neuroendocrine tumors}} | {{Neuroendocrine tumors}} | ||
{{CMG}} | {{CMG}} | ||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
== Overview == | == Overview == | ||
| Line 10: | Line 12: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Needs content]] | |||
[[Category:Disease]] | |||
[[Category:Oncology]] | |||
[[Category:Endocrinology]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 20:43, 17 September 2012
|
Neuroendocrine tumors Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Future or Investigational Therapies
Therapies based on growth factor inhibitors are in the experimental stage. These inhibitors of epidermal growth factor receptors (EGFRs), of vascular endothelial growth factor receptors (VEGFRs), and of angiopoietin-related growth factor (AGF) include imatinib, sunitinib, temozolide, thalidomide, sorafenib, and panitumumab.